Boston Scientific Pursues Dual Strategy In Addressing RotaLink Recall
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific may opt to restart production of its original Rotablator atherectomy system following the Aug. 6 recall of the next-generation RotaLink Plus, the company reported at a same-day teleconference.
You may also be interested in...
Third-Party Oversight Of Device Changes Urged In Formal Complaint
FDA should amend its policy on device modifications to require their review by an independent third party, or the agency itself, prior to marketing, according to a Jan. 14 formal complaint
Third-Party Oversight Of Device Changes Urged In Formal Complaint
FDA should amend its policy on device modifications to require their review by an independent third party, or the agency itself, prior to marketing, according to a Jan. 14 formal complaint
Boston Scientific Sees Return To Double-Digit Growth In Second Half Of 2000
Resumption of Boston Scientific's historic 20%-plus annual sales growth rate will occur the second half of 2000, the company is assuring investors, as key holes in the firm's product pipeline are filled early in the year, including release of advanced coronary stent systems.